Policy on Expanded Access to Investigational Drugs
To serve patients, BioAtla conducts clinical trials with the goal of obtaining regulatory approval of its products.
Enrollment in a clinical trial is the only method through which access to BioAtla’s investigational drugs is provided prior to their potential approval by applicable regulatory authorities and subsequent commercial availability. Our clinical trials have been designed to help demonstrate that our investigational drugs will meet the safety and efficacy standards required for approval by applicable regulatory authorities, such as the U.S. Food and Drug Administration, and therefore represent the best and safest access for patients.
Please visit https://clinicaltrials.gov for more information about current BioAtla clinical trials.
Access to BioAtla Investigational Drugs Outside of Clinical Trials
BioAtla does not currently provide expanded access options to its investigational drugs outside of its clinical trials.
BioAtla does not participate in physician-requested expanded access (also referred to as compassionate use) options to its investigational drugs.
Please visit https://clinicaltrials.gov for expanded access clinical trial alternatives.